Based on VOLGA Phase III trial results which demonstrated statistically significant and clinically meaningful improvements in event-free survival and overall survival AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI ® (durvalumab) in combination with enfortumab vedotin (EV) has been accepted and granted Priority Review in the US for the treatment of patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or have declined cisplatin-based chemotherapy

The FDA has greenlit Elevar Therapeutics' Lyrfigtu (lirafugratinib) for adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma harbouring an FGFR2 gene fusion or other rearrangement. The approval covers patients who have received prior chemotherapy or chemoimmunotherapy and who have not previously been treated with an FGFR inhibitor. The filing was supported by Phase I/II data from the ReFocus trial involving a cohort of 116 patients with unresectable o

Sept. 24, 2026 -- Amberstone Biosciences, Inc., a preclinical-stage oncology company developing pH-gated, tumor-activated T-cell engagers (TCEs), today announced a collaboration and license agreement with Shanghai Henlius Biotech, Inc., a commercial-stage biopharmaceutical company (2696.HK). Under the agreement, Amberstone will work with Henlius to apply its proprietary T-MATE™ (Tumor Microenvironment Activated ThErapeutics) platform technology to generate preclinical candidates against up to tw

Sept. 25, 2026 -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that the company will report topline results from DAYBREAK, a Phase 3 study evaluating both Zenkuda TM (tarcocimab tedromer) and KSI-501 (tabirafusp alfa tedromer) for the treatment of patients with wet age-related macular degeneration, on Monday, September 28, 2026. Kodiak Sciences (Nasdaq

FDA approval supported by data from BRAVE-AA-PEDS, the first and largest Phase 3 study specifically designed to evaluate pediatric patients with severe alopecia areata (AA) Treatment with Olumiant resulted in substantial scalp hair regrowth, as well as improvements in eyebrows and eyelashes Severe AA can result in extensive hair loss during adolescence, a formative stage of life Sept. 25, 2026 -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA)

Five-year NIH-funded program supports preclinical research, drug product manufacturing, regulatory preparation, and planned clinical studies, advancing MTTI’s EvaThera™ platform and oncology pipeline Molecular Targeting Technologies, Inc. (MTTI), a clinical-stage radiopharmaceutical company, today announced that it has been awarded a $3.17 million, five-year National Cancer Institute (NCI) grant to advance the development of ¹⁷⁷Lu-EBRGD, an investigational radiopharmaceutical targeting integrin

Anthropic has released some early findings that suggest its AI may be able to help researchers sift through the vast and expanding universe of genomic data to uncover previously hidden biology. "Today we announced the Claude-led discovery of a molecular machine that we suspect could represent a new gene editing mechanism," CEO Dario Amodei posted on social media Wednesday. "Its precise function, biotechnological utility (if any), or level of significance is not yet clear, but at minimum it is w

Primary Endpoint Achieved in CBL-0202DD Phase 2 Trial—CBL-514 delivered statistically significant pain reduction across both FAS and PP populations compared with placebo. Expansion Opportunity Beyond Dercum's Disease—Study findings support the potential development of CBL-514 for Lipedema, a condition affecting approximately 10% of women globally and representing a market opportunity of more than US$30 billion. Sept. 22, 2026 -- Caliway Biopharmaceuticals (TWSE: 6919) on September 21 announced

MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal THIO-104 advances toward key 2027 interim survival analysis Sept. 23, 2026 -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer, today announced that it has received regulatory approval by the Spanish Agency for Medicines and Medical Devices (AEMPS) and Portugal’s National A

SK pharmteco and GEMMABio Expand Rare Disease Manufacturing Collaboration Following Important Spinal Muscular Atrophy (SMA) Clinical Trial Milestone First patient dosed marks an important step for the SMA community and highlights a growing rare disease manufacturing partnership, with future GEMMABio programs expected to leverage SK pharmteco’s SKyvec™ viral vector platform Sept. 22, 2026 -- SK pharmteco announced today it has been working with Gemma Biotherapeutics (“GEMMABio”), a clinical-sta